Smallpox vaccine smashes expectations and almost triples Bavarian Nordic's revenue in the first half-yaer
It’s no secret that Bavarian Nordic’s smallpox vaccine Jynneos/Imvanex/Imvamune has been a booming business since the outbreak of mpox in May last year.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.